Gynius

What Gynius does

Gynius Plus AB is a Sweden-based privately held medical technology company that develops portable medical devices and molecular diagnostics for the early detection of cervical and breast cancer, with a particular focus on resource-limited healthcare settings. Its product portfolio comprises four core offerings: Gynocular, a portable colposcope that pairs with smartphones/tablets for cervical visualization and telecolposcopy; PCR & HPV Kits, a high-throughput HPV screening platform using lyophilized, room-temperature-stable reagents and magnetic-bead extraction capable of processing over 2,300 samples in 24 hours; Sonocular, an AI-powered portable ultrasound system with computer-vision-guided lesion detection and biopsy assistance; and Colpadvisor, a mobile application supporting colposcopy workflows. The technical differentiators center on miniaturization, elimination of cold-chain logistics through lyophilized reagents, and embedded AI for diagnostic support.

The company operates a B2B/government sales motion, selling hardware, consumables, and implementation services to national health authorities and healthcare facilities. Its primary commercial anchor is Rwanda, where it has partnered with the Rwanda Biomedical Center, the Rwanda National Reference Laboratory, and the Elekta Foundation since 2023 to support Rwanda's Mission 2027 cervical cancer elimination initiative, with deployments across at least seven districts. Revenue is generated through medical device sales (Gynocular, Sonocular), consumables (HPV testing kits and reagents), and professional services including training, laboratory construction, and telemedicine setup. Pricing is not publicly disclosed and is consistent with quote-based government and institutional procurement.

Gynius is founder-led by a team of gynecologists, headquartered in Gothenburg, Sweden, and operates with 11–50 employees. The company received a 2025 funding round led by SOSV (HAX accelerator). No institutional investors, parent companies, subsidiaries, M&A activity, or certifications/regulatory approvals are disclosed in the source material, and no revenue figures are publicly available.

Name

Gynius

Legal name

Gynius Plus AB

Website

https://gynius.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Gynius Plus AB is a Swedish medical technology company that develops portable devices and HPV testing solutions for cervical and breast cancer screening, serving government health programs and healthcare providers with deployments anchored in Rwanda's Mission 2027 elimination initiative.

Ownership category

akta.pro rank

Product category

Women's Health Diagnostic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Mammography & Breast Imaging Systems (HLAHABAF)

Keywords

• Portable colposcopy devices
• HPV screening kits
• Cervical cancer diagnostics
• Portable ultrasound systems
• Molecular diagnostic reagents

Headquarters

HQ city

Västra Frölunda

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of portable medical devices including Gynocular colposcope and Sonocular ultrasound system to healthcare providers, hospitals, and government health programs.
2. HPV Testing Kits and Reagents: Supply of PCR & HPV screening kits, lyophilized reagents, and magnetic-bead extraction consumables for laboratory testing operations.
3. Healthcare Implementation Services: End-to-end project implementation including training, clinical support, laboratory construction, and telemedicine setup services for cervical cancer screening programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Gynius Plus AB manufactures and sells portable medical devices and HPV molecular testing solutions for early detection of cervical and breast cancer. Its portfolio includes the Gynocular portable colposcope, PCR & HPV kits with room-temperature-stable reagents, the AI-enabled Sonocular portable ultrasound, and the Colpadvisor mobile application, complemented by end-to-end implementation services (training, laboratory construction, and telemedicine setup) for large-scale screening programs in resource-limited settings.

Product overview

Gynius Plus AB provides end-to-end women's healthcare solutions focused on early detection of cervical and breast cancer. The portfolio consists of four distinct products: Gynocular (a portable colposcope for cervical visualization and telecolposcopy), PCR & HPV Kits (high-throughput HPV screening solution processing 2,300+ samples per 24 hours), Sonocular (AI-powered portable ultrasound for breast cancer detection and biopsy guidance), and Colpadvisor (mobile app for colposcopy). The HPV Solution serves as the comprehensive screening platform with room-temperature-stable reagents and magnetic-bead extraction technology, enabling deployment in resource-limited settings. Together, these products support the complete screening-to-diagnosis continuum for women's cancer care.

Differentiator

Problem solved

Functional benefit

Brands

• Gynocular: A compact, portable gynecological imaging device (colposcope) that delivers high-quality cervical visualization. Designed as a mobile alternative to traditional colposcopes, it enables accurate screening, diagnosis, and follow-up examinations in clinics, hospitals, and outreach settings. Easily paired with a smartphone or tablet, it supports image capture, telemedicine, and training.
• PCR & HPV Kits
• Sonocular
• Colpadvisor

Products and services

• Gynocular® Portable Colposcope A compact, portable gynecological imaging device that delivers high-quality cervical visualization for screening, diagnosis, and follow-up examinations. Pairs with smartphones or tablets for image capture, telemedicine, and training, and operates without a fixed power source for mobile use in clinics, hospitals, and outreach settings.
• PCR & HPV Kits High-throughput HPV screening solution using room-temperature-stable, color-changing reagents and a magnetic-bead extraction system that processes over 2,300 samples within 24 hours. Eliminates cold-chain logistics requirements for laboratory testing operations.
• Sonocular Portable Ultrasound A portable, AI-powered ultrasound system for early breast cancer detection and biopsy guidance, featuring interchangeable probes, an integrated AI engine for real-time lesion identification, and computer-vision guidance for precise tissue sampling. Reduces operator variability and enhances diagnostic confidence.
• Colpadvisor Mobile Application A mobile application available on Android via Google Play Store that provides colposcopy guidance and digital health support related to cervical cancer screening and patient follow-up.
• Gynius HPV Solution Platform Comprehensive HPV screening platform enabling large-scale cervical cancer screening campaigns with lyophilized reagents and magnetic-bead extraction, stable at room temperature. Designed for cost-effective, reproducible, and scalable deployment in resource-limited settings and processes over 2,300 samples within 24 hours using Automatic Liquid Handler technology.
• Healthcare Implementation Services End-to-end project implementation services including training, clinical support, laboratory construction, and telemedicine setup delivered alongside device and reagent sales for cervical cancer screening programs in government and institutional deployments.

Quantifiable outcome

• Processing capacity increased from 654 to 2,304 samples within 24 hours with automated HPV testing technology
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered minor, core and major.

• Sweden's Ambassador for Global HealthminorStrategic or Co-development Partner · 1 November 2024In November 2024, Gynius hosted Ambassador Karin Tegmark Wisell, Sweden's Ambassador for Global Health, during a visit to Rwanda to observe cervical cancer elimination efforts, demonstrating international governmental recognition of the company's work.
• Rwanda Biomedical Center (RBC)coreStrategic or Co-development Partner · 1 January 2023Since 2023, Gynius has partnered with the Rwanda Biomedical Center (RBC) to strengthen cervical cancer screening programs across Rwanda. The partnership involves deployment of Gynocular colposcopes, high-capacity HPV testing systems, and laboratory capacity building. The collaboration has expanded from Gicumbi District to Karongi District and Bugesera District, supporting Rwanda's Mission 2027 cervical cancer elimination goal.
• Elekta FoundationcoreStrategic or Co-development Partner · 1 January 2023Gynius partners with the Elekta Foundation in supporting Rwanda's cervical cancer screening initiatives. The partnership contributes to the country's screen-and-treat strategy through innovative screening technologies and clinical tools.
• Rwanda National Reference LaboratorymajorStrategic or Co-development PartnerCollaboration with the Rwanda National Reference Laboratory for establishing HPV testing capacity, particularly for the laboratory in Gicumbi District designed to support up to 35,000 women within a three-month period.
• Local Healthcare Facilities (Rwanda)majorImplementation/ SI/ Consulting PartnerPartnership with local healthcare facilities across Rwanda districts including Gicumbi, Karongi, Bugesera, Kayonza, Ngoma, Kirehe, and Rubavu for deployment of screening technologies and clinical implementation support.
• Community Health Teams (Rwanda)majorImplementation/ SI/ Consulting PartnerCollaboration with community health teams in Rwanda for large-scale screening campaigns, HPV self-sampling programs, and patient follow-up care coordination.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Hologic: Hologic is a global women's-health diagnostics incumbent with the Aptima HPV assay, ThinPrep cytology, and mammography portfolio. It competes with Gynius in cervical screening IVDs and downstream breast imaging, with substantially greater commercial and regulatory scale.
• QIAGEN: QIAGEN's digene HC2 HPV test and QIAreach HPV molecular platforms are established HPV screening references used in LMIC programs. Gynius's PCR & HPV Kits compete with QIAGEN on throughput, workflow simplicity, and cold-chain requirements.
• GE HealthCare: GE HealthCare is a global incumbent in ultrasound, mammography, and women's-health imaging systems. It competes indirectly with Sonocular through its installed base of ultrasound systems and breast imaging equipment in hospitals and screening programs.
• Philips: Philips is a global incumbent in ultrasound and women's-health imaging, with products that compete in hospital and screening environments. It provides the broader competitive backdrop for Sonocular's portable AI-ultrasound positioning.
• Roche Diagnostics: Roche's cobas HPV test is a leading molecular HPV assay with broad global regulatory clearance and deep integration into national screening programs. It competes directly with Gynius's PCR & HPV Kits on the B2G and reference-lab side.
• Cepheid (Danaher): Cepheid's GeneXpert HPV test is a widely deployed molecular HPV platform used in national screening and HIV-related programs across Africa. It competes with Gynius's PCR & HPV Kits and brings a much larger installed base, regulatory footprint, and global-health funder relationships.

Direct peers

• MobileODT: MobileODT manufactures the EVA System, a portable smartphone-connected colposcope directly comparable to Gynius's Gynocular. Both target cervical cancer screening in resource-limited and primary-care settings, competing for the same national screening program budgets.
• Butterfly Network: Butterfly Network manufactures portable, AI-enabled point-of-care ultrasound devices used across multiple clinical workflows. Its handheld probe + AI guidance stack overlaps with Gynius's Sonocular for breast imaging and biopsy guidance, particularly in resource-limited settings.
• TruScreen: TruScreen offers a real-time cervical cancer screening device used as an adjunct or alternative to colposcopy and HPV testing. It competes with Gynius for national cervical screening program tenders in LMICs and primary-care deployments.

Emerging players

• UE LifeSciences: UE LifeSciences builds low-cost, portable breast cancer screening devices (e.g., iBreastExam) targeted at LMICs and primary-care settings. It is an emerging player in the same women's-health early-detection niche Gynius's Sonocular addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/the_gynocular
• LinkedInlinkedin.com/company/gynius-plus-ab-sweden/posts/?feedView=all
• Instagraminstagram.com/wix
• Facebookfacebook.com/gynocular

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gynius